KalVista Pharmaceuticals Acquired by Italy's Chiesi Group
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KALV?
Source: Fool
- Acquisition Boosts Stock Price: KalVista Pharmaceuticals' stock surged 38.62% to $26.67 following news that Italy's Chiesi Group will acquire the company for $27 per share in cash, indicating strong market expectations for the deal's success.
- Volume Surge: Trading volume reached 69.4 million shares, approximately 3,323% above the three-month average of 2 million shares, reflecting heightened investor interest and increased market activity surrounding the acquisition.
- Market Positioning and Product Integration: KalVista's EKTERLY, an oral therapy for hereditary angioedema affecting 1 in 50,000 people, will enhance Chiesi's portfolio of rare disease treatments, strengthening its competitive position in the market.
- Short-Term Risks and Long-Term Potential: Although KalVista was one of the most shorted stocks with a 40% short interest, Chiesi's larger international scale is expected to help the nascent treatment reach more potential patients, thereby enhancing future revenue prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.240
Low
29.00
Averages
34.38
High
39.00
Current: 19.240
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KalVista Pharmaceuticals Acquired by Italy's Chiesi Group
- Acquisition Boosts Stock Price: KalVista Pharmaceuticals' stock surged 38.62% to $26.67 following news that Italy's Chiesi Group will acquire the company for $27 per share in cash, indicating strong market expectations for the deal's success.
- Volume Surge: Trading volume reached 69.4 million shares, approximately 3,323% above the three-month average of 2 million shares, reflecting heightened investor interest and increased market activity surrounding the acquisition.
- Market Positioning and Product Integration: KalVista's EKTERLY, an oral therapy for hereditary angioedema affecting 1 in 50,000 people, will enhance Chiesi's portfolio of rare disease treatments, strengthening its competitive position in the market.
- Short-Term Risks and Long-Term Potential: Although KalVista was one of the most shorted stocks with a 40% short interest, Chiesi's larger international scale is expected to help the nascent treatment reach more potential patients, thereby enhancing future revenue prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) regarding its sale to Chiesi Group for $27.00 per share, as potential violations of shareholder rights may lead to increased compensation for investors if substantiated.
- Shareholder Rights Protection: The firm is also examining TruBridge, Inc. (NASDAQ:TBRG)'s sale to Inventurus Knowledge Solutions, Inc. for $26.25 per share, encouraging shareholders to contact the firm to understand their legal rights and options, thereby safeguarding their interests.
- Merger Transaction Review: The merger between UniFirst Corporation (NYSE:UNF) and Cintas Corporation, involving $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased consideration or other remedies to protect shareholder rights.
- Commitment to Legal Services: Halper Sadeh LLC offers risk-free legal consultations, allowing shareholders to learn about their rights and options without upfront costs, ensuring they receive due compensation in cases of potential securities fraud and corporate misconduct.
See More
Investigation into KalVista's Transaction with Chiesi Group
- Shareholder Rights Investigation: Ademi LLP is investigating KalVista (NASDAQ:KALV) for potential breaches of fiduciary duty and other legal violations related to its transaction with Chiesi Group, aiming to protect shareholder rights.
- Transaction Value and Impact: KalVista shareholders will receive $27.00 per share in cash, representing approximately $1.9 billion in equity value, which could significantly impact the company's future trajectory.
- Restrictions on Competing Bids: The transaction agreement imposes significant penalties on KalVista for accepting competing bids, potentially harming shareholder interests and leading to legal disputes.
- Board Conduct Review: We are examining whether KalVista's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decisions align with the best interests of the shareholders.
See More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion
- Acquisition Deal Size: Italy's Chiesi has agreed to acquire KalVista Pharmaceuticals for approximately $1.9 billion, a move aimed at expanding its rare disease drug portfolio, reflecting Chiesi's ambitions in the biopharmaceutical sector.
- Market Expansion Strategy: This acquisition not only enhances Chiesi's market position in the rare disease space but also leverages KalVista's R&D capabilities to accelerate the time-to-market for new drugs, thereby increasing overall business growth potential.
- Financial Impact Analysis: The transaction is expected to positively impact Chiesi's financial standing, particularly against the backdrop of rapid growth in the rare disease drug market, potentially yielding substantial long-term returns for the company.
- Industry Consolidation Trend: Chiesi's acquisition reflects a growing focus within the pharmaceutical industry on treatments for rare diseases, indicating the company's strategy to strengthen its product line and innovation capabilities through strategic acquisitions in a competitive market.
See More
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
- Acquisition Overview: Chiesi Group, an Italian pharmaceutical company, has agreed to acquire U.S. rare disease drug developer KalVista Pharmaceuticals for nearly $1.9 billion in an all-cash deal, with a purchase price of $27.00 per share, expected to close in Q3 2026.
- Product Integration Benefits: This acquisition will provide Chiesi with KalVista's FDA-approved oral treatment Ekterly (sebetralstat), specifically for hereditary angioedema, which generated $49 million in sales last year, enhancing Chiesi's rare immunology portfolio.
- Revenue Growth Potential: Chiesi aims to achieve €6 billion in revenue by the end of the decade, and the integration of Ekterly is expected to significantly contribute to this target, further driving the company's long-term growth strategy.
- Historic Transaction Impact: This deal marks Chiesi's largest acquisition to date, underscoring its commitment to expanding in the global pharmaceutical market while providing substantial returns to KalVista's shareholders.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
KalVista Pharmaceuticals Acquired by Italy's Chiesi Group
- Acquisition Boosts Stock Price: KalVista Pharmaceuticals' stock surged 38.62% to $26.67 following news that Italy's Chiesi Group will acquire the company for $27 per share in cash, indicating strong market expectations for the deal's success.
- Volume Surge: Trading volume reached 69.4 million shares, approximately 3,323% above the three-month average of 2 million shares, reflecting heightened investor interest and increased market activity surrounding the acquisition.
- Market Positioning and Product Integration: KalVista's EKTERLY, an oral therapy for hereditary angioedema affecting 1 in 50,000 people, will enhance Chiesi's portfolio of rare disease treatments, strengthening its competitive position in the market.
- Short-Term Risks and Long-Term Potential: Although KalVista was one of the most shorted stocks with a 40% short interest, Chiesi's larger international scale is expected to help the nascent treatment reach more potential patients, thereby enhancing future revenue prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) regarding its sale to Chiesi Group for $27.00 per share, as potential violations of shareholder rights may lead to increased compensation for investors if substantiated.
- Shareholder Rights Protection: The firm is also examining TruBridge, Inc. (NASDAQ:TBRG)'s sale to Inventurus Knowledge Solutions, Inc. for $26.25 per share, encouraging shareholders to contact the firm to understand their legal rights and options, thereby safeguarding their interests.
- Merger Transaction Review: The merger between UniFirst Corporation (NYSE:UNF) and Cintas Corporation, involving $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased consideration or other remedies to protect shareholder rights.
- Commitment to Legal Services: Halper Sadeh LLC offers risk-free legal consultations, allowing shareholders to learn about their rights and options without upfront costs, ensuring they receive due compensation in cases of potential securities fraud and corporate misconduct.
See More
Investigation into KalVista's Transaction with Chiesi Group
- Shareholder Rights Investigation: Ademi LLP is investigating KalVista (NASDAQ:KALV) for potential breaches of fiduciary duty and other legal violations related to its transaction with Chiesi Group, aiming to protect shareholder rights.
- Transaction Value and Impact: KalVista shareholders will receive $27.00 per share in cash, representing approximately $1.9 billion in equity value, which could significantly impact the company's future trajectory.
- Restrictions on Competing Bids: The transaction agreement imposes significant penalties on KalVista for accepting competing bids, potentially harming shareholder interests and leading to legal disputes.
- Board Conduct Review: We are examining whether KalVista's board of directors is fulfilling its fiduciary duties to all shareholders, ensuring that their decisions align with the best interests of the shareholders.
See More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion
- Acquisition Deal Size: Italy's Chiesi has agreed to acquire KalVista Pharmaceuticals for approximately $1.9 billion, a move aimed at expanding its rare disease drug portfolio, reflecting Chiesi's ambitions in the biopharmaceutical sector.
- Market Expansion Strategy: This acquisition not only enhances Chiesi's market position in the rare disease space but also leverages KalVista's R&D capabilities to accelerate the time-to-market for new drugs, thereby increasing overall business growth potential.
- Financial Impact Analysis: The transaction is expected to positively impact Chiesi's financial standing, particularly against the backdrop of rapid growth in the rare disease drug market, potentially yielding substantial long-term returns for the company.
- Industry Consolidation Trend: Chiesi's acquisition reflects a growing focus within the pharmaceutical industry on treatments for rare diseases, indicating the company's strategy to strengthen its product line and innovation capabilities through strategic acquisitions in a competitive market.
See More
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
- Acquisition Overview: Chiesi Group, an Italian pharmaceutical company, has agreed to acquire U.S. rare disease drug developer KalVista Pharmaceuticals for nearly $1.9 billion in an all-cash deal, with a purchase price of $27.00 per share, expected to close in Q3 2026.
- Product Integration Benefits: This acquisition will provide Chiesi with KalVista's FDA-approved oral treatment Ekterly (sebetralstat), specifically for hereditary angioedema, which generated $49 million in sales last year, enhancing Chiesi's rare immunology portfolio.
- Revenue Growth Potential: Chiesi aims to achieve €6 billion in revenue by the end of the decade, and the integration of Ekterly is expected to significantly contribute to this target, further driving the company's long-term growth strategy.
- Historic Transaction Impact: This deal marks Chiesi's largest acquisition to date, underscoring its commitment to expanding in the global pharmaceutical market while providing substantial returns to KalVista's shareholders.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
